Westaim appoints Andrew Rabinowitz as Chief Executive Officer of Arena Investors Group Holdings

Andrew Rabinowitz joined Arena in December 2025 and has more than 30 years of experience in the asset management industry. Before joining Arena, he was a Senior Partner at 26North, where he led the Enterprise Solutions team and served on the firms Management Committee.

Earlier, he was Co-CEO of K2 Integrity, a global risk and advisory firm. He also spent nearly 20 years at Marathon Asset Management, including as President, where he helped grow the firm's assets under management from about $250 million to more than $24 billion.

Read More:California-Based Ohmium Appoints Mark Griffin as Chief Commercial Officer

Outside of his business career, Rabinowitz co-founded the R Baby Foundation with his wife more than 17 years ago. The foundation works with over 1,200 hospitals worldwide to improve medical care for more than 13 million babies and children.

“It is an honor to assume this expanded leadership role within Westaim’s asset management business at a pivotal inflection point in the company’s history,” said Andrew Rabinowitz. “I would like to thank the Westaim Board for the trust they have placed in me and share my excitement with our team, investors and partners about the path ahead as we build on our existing businesses and expand into new and attractive markets.”

“Andrew is a proven leader who has had a significant impact on the business since he joined the company. We are pleased to appoint him to this critical leadership position as we enter this exciting period of transformation,” said Cameron MacDonald, Chief Executive Officer of Westaim. “We are confident that with Andrew at the helm alongside our deep and talented team of investment professionals.

About Arena 

Founded in 2015, Arena is a global asset management company that specialises in credit, real estate, and structured finance investments. The company works with institutional clients around the world, providing flexible financing solutions and customised investment opportunities across a wide range of industries.

Read More:argenx announces the acquisition of clinical-stage Forte Biosciences